Programmed cell death pathways, particularly apoptosis and necroptosis, play critical roles in the progressive neuronal loss observed in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Tau pathology in these 4R-tauopathies triggers both intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways, while necroptosis contributes to neuroinflammation-mediated neuronal death. Targeting these cell death pathways offers disease-modifying potential beyond symptomatic treatments.
Intrinsic (Mitochondrial) Pathway
The intrinsic apoptotic pathway is the primary mechanism of neuronal death in tauopathies[1]. Multiple triggers activate this pathway in CBS/PSP:
The Bcl-2 Family
The balance between pro- and anti-apoptotic BCL-2 proteins determines neuronal fate[2][3]:
| Protein | Function | Role in CBS/PSP |
|---|---|---|
| BCL-2 | Anti-apoptotic | Sequesters BAX/BAK; downregulated in tauopathy |
| BCL-xL | Anti-apoptotic | Critical for neuronal survival; cleaved in PSP |
| MCL-1 | Anti-apoptotic | Rapidly turned over; stress-sensitive |
| BAX | Pro-apoptotic | Oligomerizes to form MOMP pores |
| BAK | Pro-apoptotic | Direct MOMP inducer |
| BIM, PUMA | Pro-apoptotic | BH3-only sensors activated by stress |
Caspase Cascade
Caspases execute the apoptotic program:
Necroptosis is a caspase-independent, regulated necrotic cell death pathway that contributes to neuroinflammation in tauopathies[4][5][6]:
RIPK1/RIPK3/MLKL Pathway
| Component | Function | CBS/PSP Relevance |
|---|---|---|
| RIPK1 | Initiates necroptosis signaling | Elevated in PSP brain; promotes inflammation |
| RIPK3 | Mediates downstream signaling | Required for necroptosis execution |
| MLKL | Final effector | Causes membrane rupture |
Relevance to CBS/PSP
Broad-spectrum and selective caspase inhibitors have shown neuroprotective effects in preclinical models[7]:
| Compound | Target | Evidence | Status |
|---|---|---|---|
| Z-VAD-FMK | Pan-caspase | Neuroprotective in tauopathy models | Preclinical |
| Emricasan | Pan-caspase | Reduces neurodegeneration markers | Phase 2 (ALS) |
| VX-765 | Caspase-1 | Anti-inflammatory | Preclinical |
| DEVD-CHO | Caspase-3 | Selective inhibition | Preclinical |
Challenges:
BH3 Mimetics neutralize anti-apoptotic BCL-2 proteins to promote neuronal survival:
| Compound | Target | Evidence | Status |
|---|---|---|---|
| Venetoclax (ABT-199) | BCL-2 | Being explored in neurodegeneration | Preclinical |
| Navitoclax (ABT-263) | BCL-2/Bcl-xL/Bcl-w | Preclinical neuroprotection | Preclinical |
| A-1331852 | BCL-xL | Protects dopaminergic neurons | Preclinical |
BCL-2 Overexpression: Gene therapy approaches to increase BCL-2 expression show promise in models.
Targeting necroptosis offers both anti-cell death and anti-inflammatory effects:
| Compound | Target | Evidence | Status |
|---|---|---|---|
| Necrostatin-1 | RIPK1 | Protects neurons in AD/PD models | Preclinical |
| Ponatinib | RIPK1/3 | FDA-approved; neuroprotective | Repurposed |
| GSK'840 | RIPK1 | Reduces neuroinflammation | Preclinical |
| SAR-443122 | RIPK1 | Phase 1 complete | Phase 2 planned |
| Riluzole | RIPK1/ glutamate | Approved for ALS | Available |
Delivery of neurotrophic factors promotes neuronal survival by activating pro-survival pathways[8]:
| Agent | Interaction | Severity |
|---|---|---|
| Venetoclax | Minimal direct interaction | Low |
| Necrostatin-1 | Minimal direct interaction | Low |
| Emricasan | Minimal direct interaction | Low |
| CoQ10 | May enhance levodopa efficacy | Beneficial |
| MitoQ | Minimal direct interaction | Low |
| Agent | Interaction | Severity |
|---|---|---|
| Caspase inhibitors | No significant interaction | Low |
| BH3 mimetics | No significant interaction | Low |
| RIPK1 inhibitors | No significant interaction | Low |
| CoQ10 | No significant interaction | Low |
Important: Avoid combining BH3 mimetics with other pro-apoptotic agents. No known serotonin syndrome risk with these cell death modulators.
| Factor | Score | Rationale |
|---|---|---|
| Mechanistic Rationale | 8/10 | Strong: tau directly triggers both apoptosis and necroptosis; neurons in CBS/PSP show apoptotic markers |
| Clinical Evidence | 3/10 | Weak: No CBS/PSP-specific trials; mostly preclinical or AD/PD data |
| Safety Profile | 6/10 | Moderate: CNS penetration challenges; immunosuppression risk |
| Drug Interactions | 8/10 | Good: Minimal interaction with levodopa/rasagiline |
| Patient Suitability | 7/10 | Good: Early-stage patient suitable for disease-modifying approach |
| TOTAL | 32/50 | 64% |
Rationale: Given the patient's early disease stage and alpha-synuclein negative status (likely CBS/PSP tauopathy), anti-apoptosis approaches offer disease-modifying potential:
Bredesen DE. Apoptosis in neurodegenerative disorders. Nat Rev Neurosci. 2023. ↩︎
Czabotar PE, et al. Control of apoptosis by the BCL-2 family. Nat Rev Mol Cell Biol. 2023. ↩︎
Kroemer G, et al. Mitochondrial outer membrane permeabilization. Nat Rev Mol Cell Biol. 2024. ↩︎
Liu Y, et al. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019. ↩︎
Zhang Y, et al. Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease. ACS Chem Neurosci. 2022. ↩︎
Wang X, et al. Necroptosis and Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Targets. J Alzheimers Dis. 2023. ↩︎
Riedel M, et al. Caspase inhibitors in neurodegeneration. Nat Rev Drug Discov. 2023. ↩︎
Sarabi AS, et al. Neurotrophic factors in Parkinson's disease. Exp Neurol. 2024. ↩︎